CN112167639A - Composition for bidirectionally regulating morning-onset intestinal fluid balance, preparation method and application thereof - Google Patents
Composition for bidirectionally regulating morning-onset intestinal fluid balance, preparation method and application thereof Download PDFInfo
- Publication number
- CN112167639A CN112167639A CN202011049391.8A CN202011049391A CN112167639A CN 112167639 A CN112167639 A CN 112167639A CN 202011049391 A CN202011049391 A CN 202011049391A CN 112167639 A CN112167639 A CN 112167639A
- Authority
- CN
- China
- Prior art keywords
- intestinal
- parts
- body fluid
- fluid
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 70
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000012530 fluid Substances 0.000 title claims abstract description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 53
- 210000001124 body fluid Anatomy 0.000 claims abstract description 49
- 239000010839 body fluid Substances 0.000 claims abstract description 49
- 239000000047 product Substances 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 23
- 230000003204 osmotic effect Effects 0.000 claims abstract description 21
- 239000008367 deionised water Substances 0.000 claims abstract description 17
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 17
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 9
- 102000015636 Oligopeptides Human genes 0.000 claims description 36
- 108010038807 Oligopeptides Proteins 0.000 claims description 36
- 235000013305 food Nutrition 0.000 claims description 25
- 150000005846 sugar alcohols Chemical class 0.000 claims description 25
- 239000004386 Erythritol Substances 0.000 claims description 24
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 24
- 210000004369 blood Anatomy 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 24
- 235000019414 erythritol Nutrition 0.000 claims description 24
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical group OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 24
- 229940009714 erythritol Drugs 0.000 claims description 24
- 241000209140 Triticum Species 0.000 claims description 23
- 235000021307 Triticum Nutrition 0.000 claims description 23
- 239000000845 maltitol Substances 0.000 claims description 23
- 235000010449 maltitol Nutrition 0.000 claims description 23
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 23
- 229940035436 maltitol Drugs 0.000 claims description 22
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 19
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 17
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 16
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 15
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 15
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 15
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 15
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 230000033228 biological regulation Effects 0.000 claims description 14
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 14
- 239000011736 potassium bicarbonate Substances 0.000 claims description 14
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 14
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 14
- 239000001508 potassium citrate Substances 0.000 claims description 14
- 229960002635 potassium citrate Drugs 0.000 claims description 14
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 14
- 235000011082 potassium citrates Nutrition 0.000 claims description 14
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 14
- 240000008042 Zea mays Species 0.000 claims description 13
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 13
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 13
- 235000005822 corn Nutrition 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 13
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 12
- 239000001509 sodium citrate Substances 0.000 claims description 12
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 12
- 235000011083 sodium citrates Nutrition 0.000 claims description 12
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 11
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 11
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 11
- 239000000832 lactitol Substances 0.000 claims description 11
- 235000010448 lactitol Nutrition 0.000 claims description 11
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 11
- 229960003451 lactitol Drugs 0.000 claims description 11
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 239000000600 sorbitol Substances 0.000 claims description 11
- 235000010356 sorbitol Nutrition 0.000 claims description 11
- 239000000811 xylitol Substances 0.000 claims description 11
- 235000010447 xylitol Nutrition 0.000 claims description 11
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 11
- 229960002675 xylitol Drugs 0.000 claims description 11
- 210000003722 extracellular fluid Anatomy 0.000 claims description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- 229920001100 Polydextrose Polymers 0.000 claims description 8
- 239000001259 polydextrose Substances 0.000 claims description 8
- 235000013856 polydextrose Nutrition 0.000 claims description 8
- 229940035035 polydextrose Drugs 0.000 claims description 8
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims description 7
- 244000068988 Glycine max Species 0.000 claims description 7
- 235000010469 Glycine max Nutrition 0.000 claims description 7
- 239000000176 sodium gluconate Substances 0.000 claims description 7
- 235000012207 sodium gluconate Nutrition 0.000 claims description 7
- 229940005574 sodium gluconate Drugs 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 210000002977 intracellular fluid Anatomy 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 claims description 5
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 5
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 5
- 239000004224 potassium gluconate Substances 0.000 claims description 5
- 235000013926 potassium gluconate Nutrition 0.000 claims description 5
- 229960003189 potassium gluconate Drugs 0.000 claims description 5
- 235000002639 sodium chloride Nutrition 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 229960002713 calcium chloride Drugs 0.000 claims description 4
- 235000011148 calcium chloride Nutrition 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 229910001415 sodium ion Inorganic materials 0.000 claims description 4
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims description 3
- -1 composed of maltitol Chemical class 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 229910001414 potassium ion Inorganic materials 0.000 claims description 3
- 239000001540 sodium lactate Substances 0.000 claims description 3
- 235000011088 sodium lactate Nutrition 0.000 claims description 3
- 229940005581 sodium lactate Drugs 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 3
- 229940034055 calcium aspartate Drugs 0.000 claims description 2
- 229940092124 calcium citrate malate Drugs 0.000 claims description 2
- 239000004227 calcium gluconate Substances 0.000 claims description 2
- 235000013927 calcium gluconate Nutrition 0.000 claims description 2
- 229960004494 calcium gluconate Drugs 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 2
- OFNJDDJDXNMTHZ-UHFFFAOYSA-L calcium;2-aminoacetate Chemical compound [Ca+2].NCC([O-])=O.NCC([O-])=O OFNJDDJDXNMTHZ-UHFFFAOYSA-L 0.000 claims description 2
- MPCMQXRREZMSPJ-UHFFFAOYSA-L calcium;2-hydroxybutanedioate;2-hydroxypropane-1,2,3-tricarboxylic acid;pentahydrate Chemical compound O.O.O.O.O.[Ca+2].[O-]C(=O)C(O)CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MPCMQXRREZMSPJ-UHFFFAOYSA-L 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- MHJAJDCZWVHCPF-UHFFFAOYSA-L dimagnesium phosphate Chemical compound [Mg+2].OP([O-])([O-])=O MHJAJDCZWVHCPF-UHFFFAOYSA-L 0.000 claims description 2
- 229910000395 dimagnesium phosphate Inorganic materials 0.000 claims description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 210000004880 lymph fluid Anatomy 0.000 claims description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 2
- 239000001755 magnesium gluconate Substances 0.000 claims description 2
- 235000015778 magnesium gluconate Nutrition 0.000 claims description 2
- 229960003035 magnesium gluconate Drugs 0.000 claims description 2
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 229960002668 sodium chloride Drugs 0.000 claims description 2
- 229960001790 sodium citrate Drugs 0.000 claims description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 2
- 229940073490 sodium glutamate Drugs 0.000 claims description 2
- 239000001394 sodium malate Substances 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims 2
- OPSXJNAGCGVGOG-DKWTVANSSA-L Calcium L-aspartate Chemical compound [Ca+2].[O-]C(=O)[C@@H](N)CC([O-])=O OPSXJNAGCGVGOG-DKWTVANSSA-L 0.000 claims 1
- ZFXVRMSLJDYJCH-UHFFFAOYSA-N calcium magnesium Chemical compound [Mg].[Ca] ZFXVRMSLJDYJCH-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 39
- 239000006041 probiotic Substances 0.000 abstract description 16
- 235000018291 probiotics Nutrition 0.000 abstract description 16
- 206010010774 Constipation Diseases 0.000 abstract description 15
- 230000035755 proliferation Effects 0.000 abstract description 13
- 206010012735 Diarrhoea Diseases 0.000 abstract description 12
- 230000012010 growth Effects 0.000 abstract description 11
- 230000036039 immunity Effects 0.000 abstract description 11
- 239000013589 supplement Substances 0.000 abstract description 9
- 238000000855 fermentation Methods 0.000 abstract description 8
- 230000004151 fermentation Effects 0.000 abstract description 8
- 230000002708 enhancing effect Effects 0.000 abstract description 7
- 210000004185 liver Anatomy 0.000 abstract description 6
- 206010020772 Hypertension Diseases 0.000 abstract description 5
- 235000020510 functional beverage Nutrition 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 238000010791 quenching Methods 0.000 abstract description 2
- 230000035922 thirst Effects 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 description 26
- 241000186000 Bifidobacterium Species 0.000 description 21
- 230000009286 beneficial effect Effects 0.000 description 19
- 229920001542 oligosaccharide Polymers 0.000 description 19
- 150000002482 oligosaccharides Chemical class 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- 230000001954 sterilising effect Effects 0.000 description 15
- 238000004659 sterilization and disinfection Methods 0.000 description 15
- 238000011049 filling Methods 0.000 description 14
- 239000011521 glass Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 235000013325 dietary fiber Nutrition 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 229930006000 Sucrose Natural products 0.000 description 11
- 235000013350 formula milk Nutrition 0.000 description 11
- 229960004793 sucrose Drugs 0.000 description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
- 230000009102 absorption Effects 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 10
- 235000013361 beverage Nutrition 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 9
- 230000013872 defecation Effects 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 208000002925 dental caries Diseases 0.000 description 8
- 235000003599 food sweetener Nutrition 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000003765 sweetening agent Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 7
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 208000036649 Dysbacteriosis Diseases 0.000 description 6
- 208000027244 Dysbiosis Diseases 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000007140 dysbiosis Effects 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 235000019605 sweet taste sensations Nutrition 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 241000186016 Bifidobacterium bifidum Species 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010051283 Fluid imbalance Diseases 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010019133 Hangover Diseases 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000007366 host health Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000007413 intestinal health Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- GYUKEMYHXWICKF-DKWTVANSSA-N (2s)-2-aminobutanedioic acid;calcium Chemical compound [Ca].OC(=O)[C@@H](N)CC(O)=O GYUKEMYHXWICKF-DKWTVANSSA-N 0.000 description 1
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- JCSJTDYCNQHPRJ-UHFFFAOYSA-N 20-hydroxyecdysone 2,3-acetonide Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(OC2C(C(O)C(O)OC2)O)OC1 JCSJTDYCNQHPRJ-UHFFFAOYSA-N 0.000 description 1
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000609240 Ambelania acida Species 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical group OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- ZCLAHGAZPPEVDX-UHFFFAOYSA-N D-panose Natural products OC1C(O)C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC1COC1C(O)C(O)C(O)C(CO)O1 ZCLAHGAZPPEVDX-UHFFFAOYSA-N 0.000 description 1
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- YZJSUQQZGCHHNQ-UHFFFAOYSA-N Homoglutamine Chemical compound OC(=O)C(N)CCCC(N)=O YZJSUQQZGCHHNQ-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 125000003599 L-arabinosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)CO1)* 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940079172 Osmotic diuretic Drugs 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 235000016976 Quercus macrolepis Nutrition 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- SRBFZHDQGSBBOR-QMKXCQHVSA-N alpha-L-arabinopyranose Chemical compound O[C@H]1CO[C@@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-QMKXCQHVSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000010905 bagasse Substances 0.000 description 1
- JCSJTDYCNQHPRJ-FDVJSPBESA-N beta-D-Xylp-(1->4)-beta-D-Xylp-(1->4)-D-Xylp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)C(O)OC2)O)OC1 JCSJTDYCNQHPRJ-FDVJSPBESA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- DBTMGCOVALSLOR-AXAHEAMVSA-N galactotriose Natural products OC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO)O[C@@H](O[C@H]3[C@@H](O)[C@H](O)O[C@@H](CO)[C@@H]3O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O DBTMGCOVALSLOR-AXAHEAMVSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- FBJQEBRMDXPWNX-FYHZSNTMSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)C(O)O2)O)O1 FBJQEBRMDXPWNX-FYHZSNTMSA-N 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000002337 osmotic diuretic agent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- ZCLAHGAZPPEVDX-MQHGYYCBSA-N panose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ZCLAHGAZPPEVDX-MQHGYYCBSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000006068 polycondensation reaction Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003742 xyloses Chemical class 0.000 description 1
- ABKNGTPZXRUSOI-UHFFFAOYSA-N xylotriose Natural products OCC(OC1OCC(OC2OCC(O)C(O)C2O)C(O)C1O)C(O)C(O)C=O ABKNGTPZXRUSOI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The application discloses a composition for bidirectionally regulating morning starting intestinal fluid balance, a preparation method and application thereof, wherein the composition comprises the following components: 10-15 parts of deionized water, 3-8 parts of body fluid osmotic pressure regulator, 1-3 parts of body fluid ion balance regulator, 0.5-2.0 parts of body fluid acid-base balance regulator, 0.5-2.0 parts of body fluid nutritional supplement, 10-20 parts of intestinal osmotic pressure regulator and 1-2 parts of intestinal prebiotics. The functional beverage is drunk in the morning, and can quench thirst, quickly supplement the moisture of intestinal tract body fluid of a human body, promote the growth of intestinal probiotics, improve the balance of intestinal flora, ensure the proliferation effect of the intestinal probiotics, maintain proper pH value and osmotic pressure in the intestinal tract and prevent the intestinal tract burden caused by overhigh osmotic pressure; it also can discharge toxic fermentation product in intestinal tract, and has effects of reducing weight, preventing constipation or diarrhea, resisting hypertension, enhancing immunity, relieving fatigue, and protecting liver.
Description
The technical field is as follows:
the application relates to the technical field of medical health products, in particular to a composition for bidirectionally regulating morning starting intestinal fluid balance, a preparation method and application thereof.
Background art:
related studies have found that 90% of the diseases in humans are associated with intestinal unclean. Once the intestinal tract is obstructed, the defecation is not smooth, the digestion and absorption are affected, and the life health is damaged. However, with age, digestive function deteriorates and the intestine becomes unclean. In addition, when people eat coarse cereals, bad living habits can also lead to the dirtiness of the intestinal tract. The intestinal microecological imbalance refers to the change of intestinal flora, the intestinal bacteria can be divided into beneficial bacteria, harmful bacteria and neutral bacteria, the flora of healthy individuals is combined according to a certain proportion, the flora is mutually restricted and interdependent, and the ecological balance with a certain quantity and proportion is maintained. When beneficial bacteria are inhibited and harmful bacteria are increased due to various factors, the most common harm is constipation symptoms, the incidence rate of constipation is increased year by year at present, generally women are more than men, the elderly are more than young, and the current trend of constipation rejuvenation is also prominent. Constipation can cause abdominal distension, abdominal pain, diarrhea, emesis, headache, facial acne and freckle, dysphoria, listlessness, etc., and can also cause diseases such as hypertension, liver disease, breast cancer, carcinoma of large intestine, hemorrhoid, anal fissure, etc., and affect mood and health of people seriously. At present, a plurality of methods for solving the problems of intestinal microecological imbalance and related constipation exist, except for therapies of improving the immunity of the organism, removing primary diseases, reasonably using medicines and the like, probiotics and prebiotics preparations are mainly supplemented for intestinal flora at present to correct the imbalance of the intestinal flora, so that the constipation problem is solved.
The early morning is usually the period of 'highest' blood pressure level in one day, 6-9 points in the morning are generally regarded as 'devil time' when cardiovascular and cerebrovascular diseases are easy to occur, the early morning is the time when the cardiovascular and cerebrovascular diseases are high, body fluid of a human body is consumed through four channels of urine, sweat, respiration and excrement and is not supplemented yet, the body fluid is in an unbalanced state which is seriously deficient, the body fluid of the human body comprises intracellular fluid and extracellular fluid (blood, lymph, interstitial fluid and the like), the body fluid inside and outside intestinal tract cells is the same as the whole body fluid of the human body and is also in the unbalanced state, 5-7 points (in the fourth of the twelve earthly branches) in a meridian flow chart of traditional Chinese medicine are regarded as the most active time of large intestine channels, and the importance of balancing the body fluid of the intestinal tract can be seen in the; the water content of normal excrement in the intestinal tract is 30-50%, the part of liquid does not belong to body fluid, but belongs to the discharged liquid of the body fluid, and when the body fluid is deficient, the deficiency of the discharged liquid is caused. Human body fluid is in an unbalanced state in the morning, and intestinal tract intracellular and extracellular fluid is part of the body fluid and is also in a lack state, so that intestinal tract fluid (excrement fluid and beneficial flora intracellular fluid) is lack at the same time, and no product aiming at the condition of intestinal tract and body fluid imbalance in the morning is sold in the market at present.
The invention content is as follows:
in order to solve the problems in the background art, the invention provides a composition for bidirectionally regulating the balance of morning starting intestinal tract liquid, a preparation method and application thereof, which consider the supplementation of the morning starting intestinal tract and body fluid and the quick supplementation of intestinal tract discharge liquid, perform bidirectional and reasonable supplementation on the intestinal tract liquid, can effectively restore the microecological balance of the intestinal tract, and can effectively regulate the unexpected conditions of sudden cardiovascular and cerebrovascular diseases and the like caused by the unbalanced state of the morning starting body fluid and the intestinal tract.
The invention is realized by the following technical scheme:
the invention aims to provide a composition for bidirectionally regulating morning starting intestinal fluid balance, which comprises the following raw materials in parts by weight: 10-15 parts of deionized water, 3-8 parts of body fluid osmotic pressure regulator, 1-3 parts of body fluid ion balance regulator, 0.5-2.0 parts of body fluid acid-base balance regulator, 0.5-2.0 parts of body fluid nutritional supplement, 10-20 parts of intestinal osmotic pressure regulator and 1-2 parts of intestinal prebiotics.
Preferably, the body fluid osmotic pressure regulator is erythritol, and has the main characteristic that most of the erythritol is absorbed into blood after being eaten, is not decomposed and metabolized by enzymes in a human body, and is discharged through urine to mainly play a role in regulating the body fluid osmotic pressure.
Preferably, the body fluid ion balance regulator comprises potassium ions, sodium ions or selectively added calcium ions and magnesium ions; the potassium ions are one or more of potassium gluconate, potassium citrate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate and potassium chloride; the sodium ions are one or more of sodium gluconate, sodium citrate, sodium lactate, sodium chloride, sodium glutamate and DL-sodium malate; the calcium ion is one or more of calcium gluconate, calcium lactate, calcium chloride, calcium hydrogen phosphate, calcium glycinate, calcium aspartate, and calcium citrate malate; the magnesium ion is one or more of magnesium gluconate, magnesium hydrogen phosphate, magnesium sulfate, and magnesium chloride.
Preferably, the body fluid acid-base balance regulator comprises one or more of sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, sodium citrate and potassium citrate.
Preferably, the body fluid nutritional supplement comprises one or more of wheat oligopeptide, corn oligopeptide, soybean oligopeptide and L-arabinose.
Preferably, the intestinal osmotic pressure regulator is a polyhydric sugar alcohol or a polyhydric sugar alcohol mainly containing maltitol, and the polyhydric sugar alcohol is one or more of maltitol, sorbitol, mannitol, lactitol and/or xylitol.
Preferably, the intestinal prebiotics are one or more of chitosan oligosaccharide, xylooligosaccharide, fructooligosaccharide, galactooligosaccharide, isomaltooligosaccharide and polydextrose.
The second purpose of the invention is to provide a preparation method of the composition, which is characterized by comprising the following steps: and (3) sequentially adding the raw materials in the beverage into a stirring container according to the proportion, and fully stirring and uniformly mixing to obtain the beverage capable of bidirectionally regulating the intestinal liquid balance from morning to morning.
The third object of the invention is to provide the use of the composition in preparing food or health care products for regulating intestinal fluid balance, which is characterized in that: the regulation of the liquid balance of the intestinal tract comprises the regulation of body fluid in the intestinal tract tissue and the liquid regulation of the discharge in the intestinal tract; the regulation of body fluid inside the intestinal tissue comprises regulation of intestinal intracellular fluid and extracellular fluid, wherein the extracellular fluid comprises blood, lymph fluid and interstitial fluid; the liquid regulation of the intestinal discharge mainly refers to the regulation of the water quality in the intestinal discharge.
Compared with the prior art, the invention has the beneficial effects that:
1. the invention relates to a drink for bidirectionally regulating intestinal fluid balance in the morning, which is mainly used for reasonably supplementing the situation of intestinal fluid imbalance in the morning. The method considers the supplement of intestinal tract and body fluid in the morning and also considers the rapid supplement of intestinal tract discharge liquid, more importantly, the supplement is also very critical to the intracellular fluid of the beneficial intestinal flora, as the beneficial bacteria also contain a large amount of water, and simultaneously supplement nutritional supplements and prebiotics substances, so that the method can be used for bidirectionally and reasonably supplementing the intestinal tract fluid, effectively recovering the intestinal tract microecological balance and is a comprehensive treatment scheme for rapidly recovering the intestinal tract flora microecological balance.
2. The functional beverage is prepared by compounding and combining a body fluid osmotic pressure regulator, a body fluid ion balance regulator, a body fluid acid-base balance regulator, a body fluid nutritional supplement, an intestinal osmotic pressure regulator and intestinal prebiotics, and has a synergistic effect to effectively regulate intestinal microecological balance and body fluid balance, so that intestinal health and body fluid balance are comprehensively improved. Besides giving multiple effects to the beverage, the beverage can also bidirectionally adjust unexpected adverse reactions such as sudden cardiovascular and cerebrovascular diseases and the like caused by the imbalance state of body fluid and intestinal tracts in the morning. The beverage is drunk in the morning, so that the beverage can quench thirst, quickly supplement the moisture of intestinal tract body fluid of a human body, promote the growth of intestinal probiotics, improve the balance of intestinal flora, ensure the proliferation effect of the intestinal probiotics, maintain proper pH value and osmotic pressure in the intestinal tract and prevent the intestinal tract burden caused by overhigh osmotic pressure; it also can discharge toxic fermentation product in intestinal tract, and has effects of reducing weight, preventing constipation or diarrhea, resisting hypertension, enhancing immunity, relieving fatigue, and protecting liver.
The effects and introduction of each component in the invention are as follows:
erythritol is a non-caloric four-carbon multi-component sugar with sweetness of 60-80% of sucrose, is a functional sugar alcohol which is much concerned in China, and has the advantages of low energy value, high tolerance, no toxic or side effect, edible property of diabetes patients, non-cariogenic property and the like in all sugar alcohol products: 1) has "zero calorific value". Erythritol is a small molecular substance, is easily absorbed by small intestines through passive diffusion, most erythritol can enter blood circulation, and only a small amount of erythritol directly enters large intestines to serve as a carbon source for fermentation. However, erythritol entering the blood cannot be digested and decomposed by the enzyme system in the body, but is filtered out of the blood through the kidney and excreted to the outside of the body through urine. It is due to its unique metabolic properties that determines its very low energy value, only 0.84KJ/g, which is the lowest of all polyol sweeteners. 2) Can not cause dental caries. Erythritol is not available to the microorganisms in the oral cavity and therefore does not cause dental caries. 3) Does not cause blood sugar rise. Erythritol can be rapidly absorbed in small intestine, 80% of erythritol is rapidly excreted from urine, and residual decomposition product is very little, and it does not affect blood sugar level, so that it is acceptable for diabetic patients. 4) Excellent digestion tolerance. 80% of erythritol entering the body can be quickly and completely absorbed by the small intestine, so that the side effect possibly caused by unabsorbed substances is avoided.
Sorbitol: sorbitol, also known as sorbitol, can be prepared by reduction of glucose. It has sweetness comparable to glucose, but gives a feeling of richness to people. Has good moisture keeping effect, can keep food moisture, prevent drying, prevent sugar and salt from separating out and crystallizing, keep the balance of sweet, sour and bitter taste, and enhance the flavor of food.
Maltitol: hydrogenated maltose is a novel functional sweetener, has the sweetness of 85-95 percent of that of cane sugar, is not digested and absorbed in vivo, has the calorific value of only 5 percent of that of the cane sugar, does not increase the blood sugar and the cholesterol, and has attracted people's attention due to various physiological characteristics of low calorie, non-decayed tooth, indigestibility, promotion of calcium absorption and the like. Has effects in regulating blood sugar, stimulating insulin, enhancing immunity, promoting sweet taste, improving decoration, reducing color sensitivity, preventing dental caries, improving calcium absorption and retention, inhibiting excessive storage of lipase, and increasing activity of lipase. The maltitol products produced and sold in the market at present are mainly liquid maltitol syrup, and comprise different specifications of 50 percent, 75 percent, 90 percent and the like of maltitol content.
Xylitol: is a natural sweetener extracted from plant materials such as birch, oak, corn cob, bagasse, etc. Xylitol has a sweetness comparable to that of sucrose, absorbs a large amount of heat when dissolved in water, is one of all sugar alcohol sweeteners having the largest endothermic value, and therefore, when eaten in solid form, produces a pleasant cool feeling in the mouth. Xylitol can prevent dental caries. The metabolism is not regulated by insulin, and the product has a heat value of 10kJ/g, and can be used as heat energy source for diabetes patients.
Lactitol, also known as lactitol, has the main uses: 1) a good health sweetener and prebiotics. The lactitol is produced by mainly taking lactose in milk as a raw material, is natural and healthy, has sweet taste similar to that of cane sugar, has the sweetness of 30-40 percent of that of cane sugar, is fresh and bright, and has no peculiar smell. Has non-dental caries property, and can be used for sweetening candy, chocolate, jam, jelly, and dining table. The lactitol can efficiently proliferate intestinal probiotics, has the effect of regulating the health of the intestinal tract, and can be used for health care products, medical accessories and the like. And does not increase blood sugar after eating, and can be used as sweetener for diabetes patients. 2) The lactitol has low hygroscopicity, strong water binding capacity and good processing applicability of baked products. 3) Lactitol has good emulsifying property and thickening property, and can be used in dairy products, beverages, daily chemicals and the like.
Mannitol is an anhydrate or osmotic diuretic. It can raise the plasma osmotic pressure, dehydrate the tissues, dilute the plasma, filter the plasma through the glomeruli, not reabsorb by the renal tubules, keep the renal tubules with sufficient water to maintain their osmotic pressure, cause the water and electrolytes to be expelled from the body through the kidneys, produce dehydration or osmotic diuresis, and reduce intracranial and intraocular pressures. Is mainly used for treating cerebral edema and glaucoma, and preventing and treating early acute renal failure, ascites and the like.
Prebiotics are food ingredients that are not readily digestible and that beneficially affect the host by selectively stimulating the growth and activity of one or more bacteria, thereby improving host health. At present, most of the prebiotics are mainly oligosaccharides, such as galacto-oligosaccharide, inulin, fructo-oligosaccharide, xylo-oligosaccharide, isomalto-oligosaccharide, soybean oligosaccharide, chitosan and the like. The method for promoting the growth of probiotics by using prebiotics is the most effective method for solving the bottleneck problem of 'live bacteria extermination', can avoid mass death of flora due to high temperature and gastric acid stimulation and rejection of body flora to foreign flora, and can proliferate probiotics from human body, thereby safely and effectively solving various intestinal problems. Prebiotics are dietary fibers that are lost in modern diets and are beneficial to human health, a food ingredient that can be selectively fermented and alter the composition and activity of the beneficial flora in the gastrointestinal tract for host health. Prebiotics must satisfy three conditions: 1. acid and hydrolytic enzyme resistance, and is not digested and absorbed by stomach and small intestine; 2. can be fermented by intestinal flora; 3. can selectively stimulate the growth of beneficial intestinal bacteria such as bifidobacterium, lactobacillus and the like. The supplement of probiotics and prebiotics is an important means for improving the intestinal flora and microenvironment and promoting the intestinal health. The probiotics refer to living microorganisms which are beneficial to a host when supplemented in a sufficient amount, such as lactobacillus, bifidobacterium and the like, and the supplemented probiotics are obtained by directly adding a large amount of exogenous live bacteria so as to increase the number of beneficial bacteria in intestinal tracts. Most of the prebiotics are functional polysaccharides which are not digested and absorbed by human body and can be utilized by probiotics, such as inulin, fructo-oligosaccharide, galacto-oligosaccharide, stachyose, etc. The supplement of prebiotics can promote the proliferation of indigenous probiotics in the intestinal tract, thereby increasing the quantity of the probiotics and improving the intestinal flora structure. Unilateral prebiotics products have great limitations. Because of the unique personality of each oligosaccharide in each oligosaccharide prebiotics, for example, whether the prebiotics have different promotion effects and strengths on various probiotics; the inhibition ability to various harmful flora is different; in the same colon ecological environment, the fermentation time is different; the amount of gas produced during fermentation varies; the types and the amounts of short-chain fatty acids generated during fermentation decomposition are different; the ability to adhere to the wall of the large intestine varies; different fermentation activities in various regions in the large intestine, and the like, so that the single prebiotics product has great limitation.
The intestinal osmotic pressure regulator is sugar alcohol substance mainly containing maltitol, and has the main characteristic that most of the sugar alcohol substance cannot be absorbed into blood after being eaten, but enters the intestinal tract, part of the sugar alcohol substance in the intestinal tract is decomposed into short-chain fatty acid by intestinal bacteria, and the rest of the sugar alcohol substance is directly discharged out of the body. It can regulate the osmotic pressure of intestinal fluid.
The chitosan oligosaccharide is prepared by depolymerizing chitosan, is an upgraded product of chitin and chitosan products, and has incomparable superiority with chitosan. The chitosan oligosaccharide prepared by the advanced biological enzymolysis method has the advantages of low molecular weight, good water solubility, large functional effect, easy absorption by human bodies, high biological activity and the like. Meanwhile, the natural plant feed additive has the characteristics of pure nature, no radiation, no pollution, no addition and the like. The chitosan oligosaccharide has important functions of regulating immunity, resisting tumor, reducing blood lipid, regulating blood sugar, improving liver and heart and lung functions and other various physiological functions. The chitosan oligosaccharide is used as an activating factor of intestinal probiotics (such as bifidobacterium), enhances the absorption of calcium and mineral substances, and is widely applied to functional beverages and dairy products for losing weight, expelling toxin, beautifying, regulating immunity and the like.
The polydextrose is a D-glucose polymer prepared by taking glucose, sorbitol and citric acid as raw materials, blending and heating the raw materials according to a specific proportion to form a molten mixture, and then carrying out vacuum polycondensation. Polydextrose is an effective prebiotic and, after ingestion into the body, is not digested in the upper part of the gastrointestinal tract, but is fermented only in the lower part of the gastrointestinal tract, which is beneficial for the propagation of beneficial intestinal bacteria (bifidobacteria, lactobacilli) and for the inhibition of harmful bacteria such as clostridia and bacteroides. Polydextrose is a novel water-soluble dietary fiber, is widely used for manufacturing fiber-reinforced foods, and has the function of keeping intestines and stomach unobstructed after being eaten. Besides the specific effects of the insoluble dietary fiber, such as obviously increasing the volume of excrement, enhancing the defecation and reducing the risk of intestinal cancer, the polydextrose also has the functions which are not possessed or are not obvious by the insoluble dietary fiber, such as clearing away cholic acid in the body, obviously reducing serum cholesterol, more easily inducing satiety, obviously reducing blood glucose level after meal and the like.
Galacto-oligosaccharide is a functional oligosaccharide with natural properties, and the molecular structure of the galacto-oligosaccharide is generally that 1-7 galactosyl groups are connected to galactose or glucose molecules. The galacto-oligosaccharide has pure sweet taste, low heat value (7.1J/g), sweetness of 20-40 percent of that of cane sugar and strong moisture retention. Has high thermal stability under the condition of neutral pH value, and the galacto-oligosaccharide is not decomposed after being heated for 1h at 100 ℃ or 30min at 120 ℃. Comparison of galacto-oligosaccharides with fructo-oligosaccharides and isomalto-oligosaccharides: of the three oligosaccharides, galacto-oligosaccharide is the only one that can be utilized by eight beneficial bacteria in the human intestine. The galactooligosaccharide is an excellent nutrient source and an effective proliferation factor of beneficial bacteria such as bifidobacterium, lactobacillus acidophilus and the like in human intestinal tracts, and can improve the digestion and absorption functions of the human intestinal tracts. Galacto-oligosaccharide has strong acid resistance and heat resistance, and cannot lose the original characteristics due to high-temperature sterilization and decomposition of gastric acid in the processing process, but fructo-oligosaccharide does not have the characteristics. Galactooligosaccharides can be effectively utilized by both bifidobacteria B and lactic acid bacteria A. Oligosaccharides such as fructo-oligosaccharide can be used only by Lactobacillus lactis A, but not by Bifidobacterium bifidum B.
Isomaltooligosaccharides are also known as isomaltooligosaccharides, and the like. It is one kind of starch sugar, and has the main components of isomaltose, panose, isomaltotriose and oligosaccharide over tetrasaccharide with alpha-1, 6 glycosidic bond between glucose molecules. Isomaltose hypgather can effectively promote the growth and reproduction of beneficial bacteria-bifidobacterium in human body, so the isomaltose hypgather is also called bifidobacterium growth promoting factor, which is called bifidobacterium factor for short. It can promote the bifidobacterium proliferation in human body, and has the features of water soluble dietary fiber, low heat value, etc. it is one kind of functional oligosaccharide with wide application. The main effects are as follows: 1) the isomaltose hypgather is difficult to be digested by gastric enzyme, has low sweetness and low calorie, and does not basically increase blood sugar and blood fat. The isomaltooligosaccharide product contains no or very low monosaccharides and only has the heat energy of sucrose 1/6. 2) Isomaltose hypgather can promote the proliferation of bifidobacteria in intestinal tracts, inhibit the formation of harmful bacteria and putrefactive substances in the intestinal tracts, increase the content of vitamins and improve the immunity of organisms. The isomaltooligosaccharide can not be absorbed by stomach and small intestine, but directly enters large intestine, is preferentially utilized by bifidobacterium to help the bifidobacterium to propagate in large quantity, and is a bifidobacterium propagation factor; other harmful bacteria in the intestines cannot be utilized, so that the growth of the harmful bacteria can be inhibited, and the microecology in the intestines can be adjusted to a benign cycle. 3) The isomaltooligosaccharide is not utilized by streptococcus carious, and is not decomposed by oral enzyme solution, so as to prevent dental caries. 4) The isomaltooligosaccharide belongs to non-digestible oligosaccharides and has the function of water-soluble dietary fiber. Because oligosaccharides are not digested by human digestive juices, they are also called low molecular weight, non-viscous, water-soluble dietary fibers. However, the functional oligosaccharide has no thickening, hydrating and satiety effects of dietary fiber, and the health care effect of the functional oligosaccharide is derived from the unique fermentation characteristics (bifidobacterium proliferation factors). The isomaltose hypgather has the advantages over the dietary fiber that the isomaltose hypgather is low in intake, does not cause diarrhea in the recommended dose, has certain sweet taste, is completely water-soluble, does not damage the texture and flavor of the food, does not increase viscosity, does not influence the absorption of minerals and vitamins (has no embedding effect on the minerals and the vitamins), and is easy to be added into processed foods and drinks.
Fructooligosaccharides are also known as oligofructose or sucrose triose family oligosaccharides. The fructo-oligosaccharide has the double quality of definite health care function and excellent food ingredients. Has the advantages of low calorific value, no dental caries, promoting bifidobacterium proliferation, reducing blood sugar, improving serum lipid, promoting trace element absorption, etc. In recent years, among a plurality of oligosaccharide foods, fructo-oligosaccharide is recognized as 'water-soluble dietary fiber with excellent indigestibility' by international nutriologists, can bidirectionally regulate the micro-ecological balance of human bodies, belongs to a typical super-strong bifidus factor, is favored by modern food manufacturers and consumers, and is widely applied to third-generation health-care foods. Fructo-oligosaccharide is a typical prebiotic, has the effects of proliferating beneficial bacteria in intestinal tracts, balancing human micro-ecology, relaxing bowel, improving the immunity of organisms and the like, and is widely applied to the health-care food and food industries: such as infant formula, dairy products, beverages, baked food and the like.
The xylo-oligosaccharide is oligosaccharide formed by connecting 2-7 xyloses with beta-1, 4 glycosidic bonds, part of the xylo-oligosaccharide also contains arabinouronic acid and glucuronic acid side chains, and the main components of the xylo-oligosaccharide are xylobiose and xylotriose. The xylo-oligosaccharide has the functions of promoting the multiplication of beneficial bacteria in the intestinal tract, inhibiting the growth of harmful bacteria, improving the micro-ecological environment of the intestinal tract and the like. Xylo-oligosaccharide is one of the oligosaccharides which are found to have the best effect on the proliferation of bifidobacteria at present, so the xylo-oligosaccharide is called as super-strong bifidus factor, and simultaneously has the advantages of low effective dose (0.7g/d), good acid-heat stability, good processing performance, wide raw material sources and the like. Xylo-oligosaccharide can selectively promote proliferation of Bacillus bifidus. There is no enzyme system for hydrolyzing xylo-oligosaccharide in human gastrointestinal tract. Therefore, it is not digested and decomposed and directly enters the large intestine, is preferentially utilized by bifidobacteria, and has an excellent activity of promoting the proliferation of bifidobacteria. Experiments prove that the selectivity of the bifidobacterium proliferated by the xylo-oligosaccharide is greatly higher than that of other functional oligosaccharides.
The wheat oligopeptide is a micromolecular polypeptide substance obtained by extracting protein from a natural food, namely wheat protein powder, and then carrying out directional enzyme digestion and a specific small peptide separation technology. The wheat oligopeptide takes wheat gluten as a raw material and is prepared by the processes of size mixing, protease enzymolysis, separation, filtration, spray drying and the like. On 9/5/2012, the Ministry of health issued "bulletins on approval of medium-long chain fatty acid edible oil and wheat oligopeptide as new resource food" to approve wheat oligopeptide as new resource food. The efficacy and the effect are as follows: 1) has effect in inhibiting cholesterol increase. The wheat oligopeptide can promote insulin secretion, and the functional substance is oligomethionine, and can be used for regulating blood sugar of human and improving diabetes symptoms. The wheat peptide can block the action of angiotensin enzyme, thus has the effect of lowering blood pressure. One of the characteristics of the wheat oligopeptide is that the wheat oligopeptide contains homoglutamine, can effectively regulate nerves and can be used as a special nutrient substance in the case of intestinal dysfunction. 2) Has ACE inhibiting, immunoregulating, antioxidant and other bioactivity, and can stimulate lymphocyte proliferation, enhance macrophage phagocytic function, raise body's resistance to infection of outer pathogen, lower body's morbidity, etc. 3) The wheat oligopeptide is a wheat proteolysis product, can inhibit the activity of angiotensin converting enzyme, and can prevent angiotensinogen from being converted into angiotensin II which can increase blood pressure, thereby physiologically reducing blood pressure and having no effect on normal blood pressure. 4) Antioxidant activity. 5) And (3) regulating immunity. 6) Inhibiting apoptosis.
The corn oligopeptide is an oligopeptide substance prepared by carrying out enzymolysis extraction on corn protein, is a high-quality small molecular protein, has the molecular weight of about 1 percent of the molecular weight of the protein, and can be absorbed without being digested again. Is a new resource product, and can be used for lowering blood pressure, relieving hangover, protecting liver, and enhancing immunity. The corn oligopeptide has reliable safety. The corn peptide has various biological activities, such as antioxidation, hypertension resistance, immunity enhancement, fatigue resistance, liver protection and the like. It is noted that in animal and human experiments, it has been found that corn peptide also has an important but different functional property from other food-derived oligopeptides, namely, an anti-hangover effect, thereby protecting the liver.
The soybean oligopeptide is prepared by enzymolysis of soybean protein and mainly comprises short-chain polypeptide consisting of 2-10 amino acids and a small amount of free amino acids. Physiological function: reducing blood pressure. ② reducing blood fat. Regulating blood sugar. The nutrition supplement is suitable for the rehabilitation period of the operation of the digestive tract, the gastrointestinal dysfunction period caused by high temperature, overwork and the like after the operation, and the digestive dysfunction period of infants and old people. It is also suitable for athletes for supplying energy. It can promote proliferation of intestinal Bacillus bifidus and lactobacillus, and regulate intestine and stomach. Sixthly, the composition can clear free radicals in vivo and delay senility. Seventhly, has a certain weight-reducing function. The scientific practices of relevant departments of national sanitation, nutrition, medicine and the like prove that the health-care food has the following functions: 1. easy absorption, a nutritive value better than that of protein and amino acid; 2. the blood pressure is reduced without ACE inhibitor, and the blood pressure is effectively reduced; 3. fatigue resistance, namely enhancing the muscle strength and quickly recovering physical strength; 4. reducing weight, promoting muscle metabolism, and reducing obesity; 5. antioxidant I inhibits free radicals in vivo to protect cell membranes and prolong life; 6. promoting growth, super bifidus factor, enhancing beneficial bacteria, inhibiting harmful bacteria in intestinal tract, and regulating gastrointestinal function.
L-arabinose is also called arabinose, pectin sugar; is a novel low-calorie sweetener, widely exists in the peel and shell of fruits and coarse grains, and has the effect of inhibiting sucrose absorption due to the inhibition of the activity of sucrase in human intestinal tracts: clinical tests show that the L-arabinose has a blocking effect on the metabolic transformation of the sucrose, so that the L-arabinose has good application prospects in the aspects of losing weight, controlling diabetes and the like. The american medical association also lists L-arabinose as a nutritional supplement or over-the-counter for anti-obesity agents. L-arabinose is listed in a list of specific health food in Hokkaido province in Japan as a special health food additive for regulating blood sugar. In addition, L-arabinose can also inhibit body fat accumulation, so that it can be used for preventing and treating obesity, hypertension, hyperlipidemia and other diseases. L-arabinose is listed as a special health food additive for regulating blood sugar in Japan Kyoho; the American medical Association places L-arabinose as an "anti-obesity nutritional supplement or over-the-counter drug"; later, the Ministry of health of China officially approves the L-arabinose as a new resource food in 2008, and confirms the important position of the L-arabinose in the field of functional sugar.
The polyhydric sugar alcohol belongs to a functional sweetener, is an important functional food base material, and is the most common sweetener for making low-sugar foods and sucrose-free foods. The polyhydric sugar alcohol mainly comprises xylitol, sorbitol, mannitol, maltitol, lactitol and isomaltitol. Overall function of the polyhydric sugar alcohol: the metabolic pathway in the human body is irrelevant to insulin, and the glucose in blood and the insulin level are not greatly fluctuated after the food is taken, so the food can be used as special food for diabetes patients. ② the sugar alcohol is not a proper action substrate of oral microorganisms (especially mutant streptococcus), some sugar alcohols such as xylitol can even inhibit the growth and reproduction of mutant streptococcus, and the sugar alcohol can not cause dental caries after long-term intake. ③ part of polyhydric sugar alcohols (such as lactitol) have metabolic characteristics similar to those of dietary fibers, and have part of physiological functions of the dietary fibers, such as constipation prevention, intestinal flora improvement, colon cancer prevention and the like. Common features of polyhydric sugar alcohols: the sweetness is lower. ② the viscosity is lower. ③ lactose and mannitol have a high hygroscopicity, but lactitol and mannitol have a low hygroscopicity. Fourthly, the product does not participate in Maillard reaction and can be applied to baked food only by being matched with other sweeteners. Lower energy value. Sixthly, the adverse factor of the polyhydric sugar alcohol is that the excessive intake of the polyhydric sugar alcohol can cause gastrointestinal discomfort or diarrhea, but diarrhea-causing characteristics of different products are different, and the diarrhea-causing threshold value of disaccharide alcohol such as maltitol is larger than that of monosaccharide alcohol such as xylitol and sorbitol. Therefore, the maximum amount of each of these sugar alcohols should be added at the time of application, and the sugar alcohols should not be used in excess.
The specific implementation mode is as follows:
in order that the above objects, features and advantages of the present application may be more clearly understood, the present application is described in detail below with reference to specific embodiments. It should be noted that the embodiments and features of the embodiments of the present application may be combined with each other without conflict. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein in the description of the present application is for the purpose of describing particular embodiments only and is not intended to be limiting of the application.
Example 1
The formula is as follows:
preparation: adding 15 parts of deionized water, 5 parts of erythritol, 1 part of potassium citrate, 1 part of sodium citrate, 0.5 part of potassium bicarbonate, 0.5 part of wheat oligopeptide, 15 parts of maltitol and 1 part of xylo-oligosaccharide into a reaction kettle in sequence, fully stirring for dissolving, filtering, filling into a glass bottle, and performing steam sterilization at 120 ℃ for 40 minutes to obtain a finished product.
Example 2
The formula is as follows:
preparation: adding 15 parts of deionized water, 5 parts of erythritol, 1 part of potassium gluconate, 1 part of sodium gluconate, 1 part of potassium bicarbonate, 0.5 part of chitosan oligosaccharide, 0.5 part of corn oligopeptide, 12 parts of maltitol, 3 parts of xylitol and 1 part of fructo-oligosaccharide into a reaction kettle in sequence, fully stirring and dissolving, filtering, filling into a glass bottle, and performing steam sterilization at 120 ℃ for 40 minutes to obtain a finished product.
Example 3
The formula is as follows:
preparation: adding 10 parts of deionized water, 3 parts of erythritol, 0.5 part of potassium chloride, 0.45 part of sodium lactate, 0.05 part of calcium chloride, 0.5 part of potassium bicarbonate, 0.5 part of wheat oligopeptide, 10 parts of maltitol and 1 part of polydextrose into a reaction kettle, fully stirring and dissolving, filtering, filling into a glass bottle, and performing steam sterilization at 120 ℃ for 40 minutes to obtain a finished product.
Example 4
The formula is as follows:
preparation: adding 15 parts of deionized water, 8 parts of erythritol, 0.85 part of potassium citrate, 0.85 part of sodium citrate, 0.2 part of calcium chloride, 0.1 part of magnesium sulfate, 2.0 parts of sodium bicarbonate, 1.5 parts of L-arabinose, 2.0 parts of wheat oligopeptide, 10 parts of maltitol and 2.0 parts of xylo-oligosaccharide into a reaction kettle, fully stirring and dissolving, filling into a glass bottle after filtering, and performing steam sterilization at 120 ℃ for 40 minutes to obtain a finished product.
Example 5
The formula is as follows:
preparation: adding 15 parts of deionized water into a reaction kettle, sequentially adding 5 parts of erythritol, 1 part of potassium citrate, 1 part of sodium gluconate, 0.5 part of sodium bicarbonate, 0.5 part of wheat oligopeptide, 0.5 part of corn oligopeptide, 0.5 part of chitosan oligosaccharide, 20 parts of maltitol and 1.5 parts of xylo-oligosaccharide, fully stirring for dissolving, filtering, filling into a glass bottle, and performing steam sterilization at 120 ℃ for 40 minutes to obtain a finished product.
Example 6
The formula is as follows:
preparation: adding 15 parts of deionized water, 5 parts of erythritol, 1 part of potassium citrate, 1 part of sodium citrate, 0.2 part of potassium bicarbonate, 0.1 part of monopotassium phosphate, 0.3 part of dipotassium hydrogen phosphate, 0.5 part of soybean oligopeptide powder, 13 parts of maltitol, 2 parts of sorbitol and 1 part of galacto-oligosaccharide into a reaction kettle, fully stirring and dissolving, filtering, filling into a glass bottle, and performing steam sterilization at 120 ℃ for 40 minutes to obtain a finished product.
Example 7
The formula is as follows:
preparation: adding 12 parts of deionized water, 5 parts of erythritol, 0.5 part of potassium citrate, 0.5 part of sodium gluconate, 0.01 part of magnesium sulfate, 0.5 part of potassium bicarbonate, 0.5 part of wheat oligopeptide, 12 parts of maltitol, 2 parts of xylitol, 1 part of sorbitol and 1 part of xylo-oligosaccharide into a reaction kettle in sequence, fully stirring for dissolving, filtering, filling into a glass bottle, and performing steam sterilization at 120 ℃ for 40 minutes to obtain a finished product.
Example 8
The formula is as follows:
preparation: adding 15 parts of deionized water into a reaction kettle, sequentially adding 5 parts of erythritol, 1 part of potassium citrate, 1 part of sodium citrate, 0.5 part of potassium bicarbonate, 0.5 part of corn oligopeptide, 1 part of L-arabinose, 15 parts of maltitol, 0.3 part of xylo-oligosaccharide, 0.2 part of fructo-oligosaccharide and 0.5 part of galacto-oligosaccharide, fully stirring for dissolving, filtering, filling into a glass bottle, and performing steam sterilization at 120 ℃ for 40 minutes to obtain a finished product.
Example 9
The formula is as follows:
preparation: adding 14 parts of deionized water, 5 parts of erythritol, 1 part of potassium citrate, 1 part of sodium citrate, 0.5 part of potassium bicarbonate, 0.5 part of wheat oligopeptide, 0.5 part of corn oligopeptide, 0.2 part of soybean oligopeptide, 0.5 part of L-arabinose, 0.1 part of chitosan oligosaccharide, 15 parts of maltitol and 1 part of fructo-oligosaccharide into a reaction kettle in sequence, fully stirring and dissolving, filtering, filling into a glass bottle, and performing steam sterilization at 120 ℃ for 40 minutes to obtain a finished product.
Example 10:
the formula is as follows:
preparation: adding 15 parts of deionized water into a reaction kettle, sequentially adding 5 parts of erythritol, 1 part of potassium citrate, 1 part of sodium citrate, 0.5 part of potassium bicarbonate, 0.5 part of wheat oligopeptide, 0.5 part of corn oligopeptide, 0.5 part of soybean oligopeptide, 0.1 part of L-arabinose, 0.1 part of chitosan oligosaccharide, 12 parts of maltitol, 2 parts of xylitol, 1 part of sorbitol, 1 part of fructo-oligosaccharide and 1 part of polydextrose, fully stirring for dissolving, filtering, filling into a glass bottle, and performing steam sterilization at 120 ℃ for 40 minutes to obtain a finished product.
Verification example 1: functional evaluation
100 patients with chronic constipation and intestinal dysbacteriosis are selected and divided into five groups, and the drinks of the embodiment 1-2 are respectively taken 1 time every morning and 450mL each time, and after 7 days of taking, diarrhea is observed and bifidobacteria in per gram of feces are counted, and the results are shown in Table 1.
Comparative example 1: adding 15 parts of deionized water, 1 part of potassium citrate, 1 part of sodium citrate, 0.5 part of potassium bicarbonate, 0.5 part of wheat oligopeptide, 15 parts of maltitol and 1 part of xylo-oligosaccharide into a reaction kettle in sequence, fully stirring and dissolving, filtering, filling into a glass bottle, and performing steam sterilization at 120 ℃ for 40 minutes to obtain a finished product.
Comparative example 2: adding 15 parts of deionized water, 5 parts of erythritol, 1 part of potassium gluconate, 1 part of sodium gluconate, 1 part of potassium bicarbonate, 0.5 part of chitosan oligosaccharide and 1 part of fructo-oligosaccharide into a reaction kettle in sequence, fully stirring for dissolving, filtering, filling into a glass bottle, and performing steam sterilization at 120 ℃ for 40 minutes to obtain a finished product.
Blank group: the patient drinks 450mL of mild saline warm water every morning.
The criteria for determination are as follows:
and (3) healing: defecation is normal, and accompanying symptoms disappear completely;
the effect is shown: the constipation is obviously improved, the interval time and the stool quality are close to normal, or the defecation is slightly flat, the interval time is within 72h, and most of accompanying symptoms disappear;
the method has the following advantages: the defecation time interval is shortened by 1 day, or the constipation is dry and improved, and the accompanying symptoms are all improved;
and (4) invalidation: constipation and accompanying symptoms were not improved.
TABLE 1 comparison of therapeutic effects
As can be seen from the above table, the effect of the invention is better after taking the product in examples 1-2, while the effect of comparative examples 1 and 2 is certain, but the effect is slower, and the improvement of the intestinal environment and the body fluid environment is more obvious under the reasonable configuration of the raw materials. The result shows that over 90 percent of volunteers obviously improve constipation and intestinal dysbacteriosis after taking the product for 1 week. Therefore, the beverage has positive effects and influences on the aspects of improving constipation and relieving intestinal dysbacteriosis.
Verification example 2: functional evaluation
80 patients with chronic diarrhea and intestinal dysbacteriosis are selected and divided into five groups, and the drinks of the embodiment 1-2 are respectively taken 1 time every morning and 450mL each time, and after 7 days of taking, diarrhea is observed and bifidobacteria in per gram of feces are counted, and the results are shown in Table 2.
Comparative example 1: adding 15 parts of deionized water, 1 part of potassium citrate, 1 part of sodium citrate, 0.5 part of potassium bicarbonate, 0.5 part of wheat oligopeptide, 15 parts of maltitol and 1 part of xylo-oligosaccharide into a reaction kettle in sequence, fully stirring and dissolving, filtering, filling into a glass bottle, and performing steam sterilization at 120 ℃ for 40 minutes to obtain a finished product.
Comparative example 2: adding 15 parts of deionized water, 5 parts of erythritol, 1 part of potassium gluconate, 1 part of sodium gluconate, 1 part of potassium bicarbonate, 0.5 part of chitosan oligosaccharide and 1 part of fructo-oligosaccharide into a reaction kettle in sequence, fully stirring for dissolving, filtering, filling into a glass bottle, and performing steam sterilization at 120 ℃ for 40 minutes to obtain a finished product.
Blank group: the patient drinks 450mL of mild saline warm water every morning.
The criteria for determination are as follows:
and (3) healing: defecation is carried out once or twice a day, the feces are shaped, the abdominal pain disappears, and the physical strength is recovered.
The effect is shown: defecation is carried out once or twice a day, the feces are shaped, and the abdominal pain disappears, so that the force is relatively weak.
The method has the following advantages: defecation is two to three times a day, the feces are shaped, and the abdominal pain is relieved, so that the force is relatively weak.
And (4) invalidation: defecation is carried out more than three times every day, and water samples are thin and defecate, accompanied by abdominal pain and weakness.
TABLE 2 comparison of therapeutic effects
As can be seen from the above table, the effect of the invention is better after taking the product in examples 1-2, while the effect of comparative examples 1 and 2 is certain, but the effect is slower, and the improvement of the intestinal environment and the body fluid environment is more obvious under the reasonable configuration of the raw materials. The result shows that more than 90 percent of volunteers have obvious improvement on diarrhea and intestinal dysbacteriosis after taking the product for 1 week. Therefore, the beverage of the invention has positive effects and influences on the aspects of improving diarrhea and relieving intestinal dysbacteriosis.
Claims (10)
1. The composition for bidirectionally regulating morning starting intestinal fluid balance is characterized by comprising the following raw materials in parts by weight: 10-15 parts of deionized water, 3-8 parts of body fluid osmotic pressure regulator, 1-3 parts of body fluid ion balance regulator, 0.5-2.0 parts of body fluid acid-base balance regulator, 0.5-2.0 parts of body fluid nutritional supplement, 10-20 parts of intestinal osmotic pressure regulator and 1-2 parts of intestinal prebiotics.
2. The composition of claim 1, wherein said osmolality adjusting agent is erythritol.
3. The composition of claim 1, wherein the body fluid ion balance modifier comprises potassium sodium ions or optionally added calcium magnesium ions; the potassium ions are one or more of potassium gluconate, potassium citrate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate and potassium chloride; the sodium ions are one or more of sodium gluconate, sodium citrate, sodium lactate, sodium chloride, sodium glutamate and DL-sodium malate; the calcium ion is one or more of calcium gluconate, calcium lactate, calcium chloride, calcium hydrogen phosphate, calcium glycinate, calcium aspartate, and calcium citrate malate; the magnesium ion is one or more of magnesium gluconate, magnesium hydrogen phosphate, magnesium sulfate, and magnesium chloride.
4. The composition of claim 1, wherein the body fluid acid-base equilibrium modifier comprises one or more of sodium bicarbonate, potassium bicarbonate, sodium carbonate, potassium carbonate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, sodium citrate, and potassium citrate.
5. The composition of claim 1, wherein the humoral nutritional supplement comprises one or more of wheat oligopeptide, corn oligopeptide, soybean oligopeptide, L-arabinose.
6. The composition according to claim 1, wherein the intestinal osmotic pressure regulator is a polyhydric sugar alcohol or a polyhydric sugar alcohol mainly composed of maltitol, and the polyhydric sugar alcohol is one or more of maltitol, sorbitol, mannitol, lactitol and/or xylitol.
7. The composition according to claim 1, wherein the intestinal prebiotics are one or more of chitosan oligosaccharide, xylooligosaccharide, fructooligosaccharide, galactooligosaccharide, isomaltooligosaccharide or polydextrose.
8. A method of preparing the composition of any one of claims 1 to 7, comprising the steps of: the raw materials in the composition are sequentially added into a stirring container according to the proportion, and are fully stirred and uniformly mixed to obtain the drink for bidirectionally regulating the intestinal fluid balance from morning to morning.
9. Use of a composition according to any one of claims 1 to 7 in the manufacture of a food or health product or medicament for regulating the intestinal fluid balance.
10. Use of a composition according to claim 9 for the preparation of a food or health product or pharmaceutical product for regulating the intestinal fluid balance, wherein: the regulation of the liquid balance of the intestinal tract comprises the regulation of body fluid in the intestinal tract tissue and the liquid regulation of the discharge in the intestinal tract; the regulation of body fluid inside the intestinal tissue comprises regulation of intestinal intracellular fluid and extracellular fluid, wherein the extracellular fluid comprises blood, lymph fluid and interstitial fluid; the liquid regulation of the intestinal discharge mainly refers to the regulation of the water quality in the intestinal discharge.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011049391.8A CN112167639A (en) | 2020-09-29 | 2020-09-29 | Composition for bidirectionally regulating morning-onset intestinal fluid balance, preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011049391.8A CN112167639A (en) | 2020-09-29 | 2020-09-29 | Composition for bidirectionally regulating morning-onset intestinal fluid balance, preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112167639A true CN112167639A (en) | 2021-01-05 |
Family
ID=73945893
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011049391.8A Pending CN112167639A (en) | 2020-09-29 | 2020-09-29 | Composition for bidirectionally regulating morning-onset intestinal fluid balance, preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112167639A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114223877A (en) * | 2021-11-17 | 2022-03-25 | 武汉益鼎天养生物科技有限公司 | Bamboo salt composition with intestinal flora regulating function and application thereof |
CN115671041A (en) * | 2022-08-24 | 2023-02-03 | 纽湃腾(北京)医药科技有限公司 | Concentrated lactitol oral liquid and preparation method and application thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004067037A1 (en) * | 2003-01-30 | 2004-08-12 | Ajinomoto Co., Inc. | Intestinal environment controlling agent for oral use and normal intestinal flora growing kit for oral use |
WO2012146881A1 (en) * | 2011-04-28 | 2012-11-01 | Roquette Freres | Anti-inflammatory composition for the intestine including maltitol |
CN110179121A (en) * | 2019-05-13 | 2019-08-30 | 湖南唯乐可健康产业有限公司 | It is a kind of to improve the 5-linked probiotic composition of enteron aisle, compound solid beverage and its preparation method and application |
CN111493249A (en) * | 2020-05-25 | 2020-08-07 | 山东博奥克生物科技有限公司 | Prebiotics plant polypeptide beverage and preparation method thereof |
-
2020
- 2020-09-29 CN CN202011049391.8A patent/CN112167639A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004067037A1 (en) * | 2003-01-30 | 2004-08-12 | Ajinomoto Co., Inc. | Intestinal environment controlling agent for oral use and normal intestinal flora growing kit for oral use |
WO2012146881A1 (en) * | 2011-04-28 | 2012-11-01 | Roquette Freres | Anti-inflammatory composition for the intestine including maltitol |
CN110179121A (en) * | 2019-05-13 | 2019-08-30 | 湖南唯乐可健康产业有限公司 | It is a kind of to improve the 5-linked probiotic composition of enteron aisle, compound solid beverage and its preparation method and application |
CN111493249A (en) * | 2020-05-25 | 2020-08-07 | 山东博奥克生物科技有限公司 | Prebiotics plant polypeptide beverage and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
潘道东: "《功能性食品添加剂》", 31 January 2006, 中国轻工业出版社 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114223877A (en) * | 2021-11-17 | 2022-03-25 | 武汉益鼎天养生物科技有限公司 | Bamboo salt composition with intestinal flora regulating function and application thereof |
CN115671041A (en) * | 2022-08-24 | 2023-02-03 | 纽湃腾(北京)医药科技有限公司 | Concentrated lactitol oral liquid and preparation method and application thereof |
CN115671041B (en) * | 2022-08-24 | 2024-03-01 | 纽湃腾(北京)医药科技有限公司 | Concentrated lactitol oral liquid and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104643250B (en) | It is a kind of can bidirectional modulation body weight improve inferior health solid beverage | |
CN102273585B (en) | Health-care porridge with effect of relaxing bowel and preparation method thereof | |
CN110338402A (en) | A kind of compound probiotic powder and preparation method thereof | |
CN106723087A (en) | A kind of tablet containing kelp dietary fiber and preparation method thereof | |
CN111406800A (en) | Low-GI yogurt suitable for diabetics and preparation method thereof | |
CN111227261A (en) | Prebiotic composition and application thereof | |
CN106690331A (en) | Kelp dietary fiber granules and preparation method thereof | |
CN106036342A (en) | Dietary supplement solid beverage suitable for diabetic population and preparation method of dietary supplement solid beverage | |
JP2006502103A (en) | Condensed palatinose and method for producing the same | |
CN102511861A (en) | Thickened red jujube pulp added with oligosaccharide | |
CN111387381A (en) | Lonicera edulis compound fruit juice beverage and preparation method thereof | |
CN105325883A (en) | Preparation method of modified soybean dietary fiber powder with sugar and lipid-lowering effects | |
CN113632851A (en) | Multifunctional children growth milk powder and preparation method thereof | |
CN112704237A (en) | Vegetable peptide fat-reducing composition and eating method thereof | |
CN114271502A (en) | Clam peptide compound for protecting cardiovascular system and kidney and application thereof | |
CN112167639A (en) | Composition for bidirectionally regulating morning-onset intestinal fluid balance, preparation method and application thereof | |
CN114711374A (en) | Composite nutrient powder of ferment fibre and its preparation method | |
CN113598231A (en) | Sucrose-free yogurt added with composite dietary fiber and humanized probiotics and preparation method thereof | |
JPS62220169A (en) | Fluid food | |
WO2005056022A1 (en) | Enteropathy ameliorating composition | |
CN116173076A (en) | Liver-protecting and alcohol-dispelling composition and application thereof | |
CN114191515A (en) | Oral gel for dispelling dampness, invigorating stomach and improving immunity and preparation method thereof | |
CN115702654A (en) | Middle-aged and old-aged modified goat milk powder assisting in reducing blood sugar and preparation method thereof | |
JP2009034017A (en) | Diet food | |
CN112617204A (en) | Arabic gum composition with bowel relaxing and constipation relieving effects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |